Please assess the completion status of the following clinical trial:

Trial Title: MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Patient is highly unlikely to conceive~* Patient meets one of the 3 categories is naïve to all antihyperglycemic agent (AHA) therapies, or is non-naïve based upon the patient's current diet, medical regimen and screening A1c patient is currently not on AHA with a screening A1c \>=7.5 % and =\<11.0 % patient is currently on either metformin pr sulfonylurea monotherapy with a screening A1c \>=7.0 % and =\<9.0 %~Exclusion Criteria~* Patient has a history of type 1 diabetes mellitus or history of ketoacidosis or has C=peptide value of =\<0.8 ng/mL~* Patient has previously been treated with insulin, thiazolidinedione (TZD) (rosiglitazone or pioglitazone), any Dipeptidyl peptidase-4 (DPP-4) inhibitor (sitagliptin, vildagliptin, or alogliptin), exenatide or has previously been in a clinical study with any DPP-4 inhibitor or incretin mimetic~* Patient is on a weight loss program and is not in the maintenance phase or has started a weight loss medication (e.g. orlistat or sibutramine) within the prior 8 weeks~* Patient has undergone surgery within the prior 30 days or has major surgery planned during the study~* Patient has a medical history of active liver disease including chronic active hepatitis B or C or symptomatic gallbladder disease including primary biliary cirrhosis~* Patient has received treatment with an investigational product within 12 weeks prior to Visit 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 78 Years
- Healthy Volunteers: f

Study Arms:
- Sitagliptin 100 mg (Type: EXPERIMENTAL): None
- Pioglitazone 15 mg (Type: EXPERIMENTAL): None
- Pioglitazone 30 mg (Type: EXPERIMENTAL): None
- Pioglitazone 45 mg (Type: EXPERIMENTAL): None
- Sitagliptin 100 mg/ Pioglitazone 15 mg (Type: EXPERIMENTAL): None
- Sitagliptin 100 mg/ Pioglitazone 30 mg (Type: EXPERIMENTAL): None
- Sitagliptin 100 mg/ Pioglitazone 45 mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).